During the last session, Calidi Biotherapeutics Inc (AMEX:CLDI)’s traded shares were 1.13 million, with the beta value of the company hitting 0.60. At the end of the trading day, the stock’s price was $1.18, reflecting an intraday gain of 6.30% or $0.07. The 52-week high for the CLDI share is $26.30, that puts it down -2128.81 from that peak though still a striking 38.14% gain since the share price plummeted to a 52-week low of $0.73. The company’s market capitalization is $13.78M, and the average intraday trading volume over the past 10 days was 1.48 million shares, and the average trade volume was 298.59K shares over the past three months.
Calidi Biotherapeutics Inc (AMEX:CLDI) trade information
Calidi Biotherapeutics Inc (CLDI) registered a 6.30% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 6.30% in intraday trading to $1.18, hitting a weekly high. The stock’s 5-day price performance is 40.46%, and it has moved by 7.26% in 30 days. Based on these gigs, the overall price performance for the year is -94.59%. The short interest in Calidi Biotherapeutics Inc (AMEX:CLDI) is 0.11 million shares and it means that shorts have 1.88 day(s) to cover.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The consensus price target of analysts on Wall Street is $5.5, which implies an increase of 78.55% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $2 and $9 respectively. As a result, CLDI is trading at a discount of -662.71% off the target high and -69.49% off the low.
Calidi Biotherapeutics Inc (CLDI) estimates and forecasts
Statistics show that Calidi Biotherapeutics Inc has outperformed its competitors in share price, compared to the industry in which it operates. Calidi Biotherapeutics Inc (CLDI) shares have gone down -41.30% during the last six months, with a year-to-date growth rate more than the industry average at 74.68% against 17.30.
While earnings are projected to return 77.06% in 2024.
CLDI Dividends
Calidi Biotherapeutics Inc is due to release its next quarterly earnings in December. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Calidi Biotherapeutics Inc (AMEX:CLDI)’s Major holders
Calidi Biotherapeutics Inc insiders own 18.16% of total outstanding shares while institutional holders control 2.45%, with the float percentage being 3.00%.
